Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience

Area of Science:

• Oncology
• Hematology
• Immunology

Background:

• Osteosarcoma (OST) patient outcomes may be influenced by neutrophil-to-lymphocyte ratio (NLR) at diagnosis and early lymphocyte recovery during chemotherapy.
• Previous research suggests a link between specific hematological parameters and treatment efficacy in OST.

Purpose of the Study:

• To investigate the prognostic significance of various hemogram parameters in OST patients.
• To evaluate the predictive value of early chemotherapy-induced changes in blood counts for survival outcomes.

Main Methods:

• Retrospective analysis of a consecutive cohort of 164 OST patients from the French OS2006 trial.
• Assessment of hemogram parameters at diagnosis and during high-dose methotrexate and etoposide/ifosfamide (M-EI) chemotherapy.

Main Results:

• No significant prognostic value was found for blood counts at diagnosis or early lymphocyte recovery at Day 14.
• An elevated NLR at Day 1 of the first etoposide/ifosfamide chemotherapy (NLR-W4) was associated with reduced overall survival (OS) in both univariate and multivariate analyses.
• Each unit increase in NLR-W4 correlated with a 30% increased risk of death, even after adjusting for histological response and metastatic status.

Conclusions:

• NLR-W4 emerges as a potential early biomarker for predicting survival in osteosarcoma patients treated with M-EI chemotherapy.
• Further research is needed to confirm the prognostic utility of NLR and elucidate the underlying immune mechanisms in disease surveillance.